High levels of Serum Angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

Efstathios Kastritis (1) , Maria Roussou (2) , Michalis Michael (3) , Maria Gavriatopoulou (2) , Evridiki Michalis (4) , Magdalini Migkou (2) , Sossana Delimpassi (3) , Marie-Christine Kyrtsonis (5) , Dimitrios Gogos (4) , Konstantinos Liapis (3) , Evangelia Charitaki (6) , Panagiotis Repoussis (7) , Evangelos Terpos (2, 8) , Meletios Athanasios Dimopoulos (2, 9)

1 Department of Clinical Therapeutics
2 Department of Clinical Therapeutics
3 Hematology-Lymphoma
4 Hematology-Lymphoma
5 Hematology-Lymphoma
6 Renal and Transplantation Unit
7 Hematology-Lymphoma
8 Haematology
9 Clinical Therapeutics

We evaluated the serum levels of five angiogenic cytokines in 82 patients with primary systemic amyloidosis (AL). Angiopoietin-1, VEGF bFGF and angiogenin were higher in AL patients than in controls (n=35) and newly-diagnosed, symptomatic, myeloma patients (n=35). The ratio of Angiopoetin-1/Angiopoetin-2 was lower in AL compared to controls but higher compared to myeloma patients. Angiopoetin-2 correlated with indices of cardiac dysfunction; however, none of the angiogenic growth factors was of prognostic significance. The increased levels of angiogenic cytokines observed in AL seem to represent either a toxic effect of amyloid fibrils or light chains, or a compensatory response to organ dysfunction.

Mots clés: Medicine

Efstathios Kastritis, Maria Roussou, Michalis Michael, Maria Gavriatopoulou, Evridiki Michalis, et al.. High levels of Serum Angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. British Journal of Haematology, 2010, 150 (5), pp.587. ⟨10.1111/j.1365-2141.2010.08288.x⟩. ⟨hal-00553272⟩